These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
125 related articles for article (PubMed ID: 36594442)
1. Evaluation of a Live-Attenuated Human Parainfluenza Virus Type 2 Vaccine in Adults and Children. Karron RA; Herbert K; Wanionek K; Schmidt AC; Schaap-Nutt A; Collins PL; Buchholz UJ J Pediatric Infect Dis Soc; 2023 Apr; 12(3):173-176. PubMed ID: 36594442 [TBL] [Abstract][Full Text] [Related]
2. Evaluation of a Live-Attenuated Human Parainfluenza Type 1 Vaccine in Adults and Children. Karron RA; San Mateo J; Thumar B; Schaap-Nutt A; Buchholz UJ; Schmidt AC; Bartlett EJ; Murphy BR; Collins PL J Pediatric Infect Dis Soc; 2015 Dec; 4(4):e143-6. PubMed ID: 26582883 [TBL] [Abstract][Full Text] [Related]
3. Recombinant human parainfluenza virus type 2 vaccine candidates containing a 3' genomic promoter mutation and L polymerase mutations are attenuated and protective in non-human primates. Nolan SM; Skiadopoulos MH; Bradley K; Kim OS; Bier S; Amaro-Carambot E; Surman SR; Davis S; St Claire M; Elkins R; Collins PL; Murphy BR; Schaap-Nutt A Vaccine; 2007 Aug; 25(34):6409-22. PubMed ID: 17658669 [TBL] [Abstract][Full Text] [Related]
4. Evaluation of a Live Attenuated Human Metapneumovirus Vaccine in Adults and Children. Karron RA; San Mateo J; Wanionek K; Collins PL; Buchholz UJ J Pediatric Infect Dis Soc; 2018 Feb; 7(1):86-89. PubMed ID: 28444226 [TBL] [Abstract][Full Text] [Related]
5. Live-attenuated intranasal parainfluenza virus type 2 vaccine candidates developed by reverse genetics containing L polymerase protein mutations imported from heterologous paramyxoviruses. Nolan SM; Surman SR; Amaro-Carambot E; Collins PL; Murphy BR; Skiadopoulos MH Vaccine; 2005 Sep; 23(39):4765-74. PubMed ID: 15964103 [TBL] [Abstract][Full Text] [Related]
6. Evaluation of two chimeric bovine-human parainfluenza virus type 3 vaccines in infants and young children. Karron RA; Thumar B; Schappell E; Surman S; Murphy BR; Collins PL; Schmidt AC Vaccine; 2012 Jun; 30(26):3975-81. PubMed ID: 22178099 [TBL] [Abstract][Full Text] [Related]
7. A live human parainfluenza type 3 virus vaccine is attenuated and immunogenic in young infants. Karron RA; Belshe RB; Wright PF; Thumar B; Burns B; Newman F; Cannon JC; Thompson J; Tsai T; Paschalis M; Wu SL; Mitcho Y; Hackell J; Murphy BR; Tatem JM Pediatr Infect Dis J; 2003 May; 22(5):394-405. PubMed ID: 12792378 [TBL] [Abstract][Full Text] [Related]
8. A live attenuated recombinant chimeric parainfluenza virus (PIV) candidate vaccine containing the hemagglutinin-neuraminidase and fusion glycoproteins of PIV1 and the remaining proteins from PIV3 induces resistance to PIV1 even in animals immune to PIV3. Tao T; Davoodi F; Cho CJ; Skiadopoulos MH; Durbin AP; Collins PL; Murphy BR Vaccine; 2000 Jan; 18(14):1359-66. PubMed ID: 10618533 [TBL] [Abstract][Full Text] [Related]
9. Human parainfluenza virus type 2 V protein inhibits interferon production and signaling and is required for replication in non-human primates. Schaap-Nutt A; D'Angelo C; Scull MA; Amaro-Carambot E; Nishio M; Pickles RJ; Collins PL; Murphy BR; Schmidt AC Virology; 2010 Feb; 397(2):285-98. PubMed ID: 19969320 [TBL] [Abstract][Full Text] [Related]
10. Growth restriction of an experimental live attenuated human parainfluenza virus type 2 vaccine in human ciliated airway epithelium in vitro parallels attenuation in African green monkeys. Schaap-Nutt A; Scull MA; Schmidt AC; Murphy BR; Pickles RJ Vaccine; 2010 Mar; 28(15):2788-98. PubMed ID: 20139039 [TBL] [Abstract][Full Text] [Related]
11. Recombinant human parainfluenza virus type 2 with mutations in V that permit cellular interferon signaling are not attenuated in non-human primates. Schaap-Nutt A; D'Angelo C; Amaro-Carambot E; Nolan SM; Davis S; Wise SM; Higgins C; Bradley K; Kim O; Mayor R; Skiadopoulos MH; Collins PL; Murphy BR; Schmidt AC Virology; 2010 Oct; 406(1):65-79. PubMed ID: 20667570 [TBL] [Abstract][Full Text] [Related]
12. Replacement of the ectodomains of the hemagglutinin-neuraminidase and fusion glycoproteins of recombinant parainfluenza virus type 3 (PIV3) with their counterparts from PIV2 yields attenuated PIV2 vaccine candidates. Tao T; Skiadopoulos MH; Davoodi F; Riggs JM; Collins PL; Murphy BR J Virol; 2000 Jul; 74(14):6448-58. PubMed ID: 10864657 [TBL] [Abstract][Full Text] [Related]
13. Human parainfluenza 2 & 4: Clinical and genetic epidemiology in the UK, 2013-2017, reveals distinct disease features and co-circulating genomic subtypes. Chellapuri A; Smitheman M; Chappell JG; Clark G; Howson-Wells HC; Berry L; Ball JK; Irving WL; Tarr AW; McClure CP Influenza Other Respir Viruses; 2022 Nov; 16(6):1122-1132. PubMed ID: 35672928 [TBL] [Abstract][Full Text] [Related]
14. A live human parainfluenza type 3 virus vaccine is attenuated and immunogenic in healthy infants and children. Karron RA; Wright PF; Newman FK; Makhene M; Thompson J; Samorodin R; Wilson MH; Anderson EL; Clements ML; Murphy BR J Infect Dis; 1995 Dec; 172(6):1445-50. PubMed ID: 7594701 [TBL] [Abstract][Full Text] [Related]
15. Attenuated Human Parainfluenza Virus Type 1 (HPIV1) Expressing the Fusion Glycoprotein of Human Respiratory Syncytial Virus (RSV) as a Bivalent HPIV1/RSV Vaccine. Mackow N; Amaro-Carambot E; Liang B; Surman S; Lingemann M; Yang L; Collins PL; Munir S J Virol; 2015 Oct; 89(20):10319-32. PubMed ID: 26223633 [TBL] [Abstract][Full Text] [Related]
16. Generation of recombinant human parainfluenza virus type 1 vaccine candidates by importation of temperature-sensitive and attenuating mutations from heterologous paramyxoviruses. Newman JT; Riggs JM; Surman SR; McAuliffe JM; Mulaikal TA; Collins PL; Murphy BR; Skiadopoulos MH J Virol; 2004 Feb; 78(4):2017-28. PubMed ID: 14747566 [TBL] [Abstract][Full Text] [Related]
17. A live attenuated bovine parainfluenza virus type 3 vaccine is safe, infectious, immunogenic, and phenotypically stable in infants and children. Karron RA; Wright PF; Hall SL; Makhene M; Thompson J; Burns BA; Tollefson S; Steinhoff MC; Wilson MH; Harris DO J Infect Dis; 1995 May; 171(5):1107-14. PubMed ID: 7751684 [TBL] [Abstract][Full Text] [Related]
18. Construction of a live-attenuated bivalent vaccine virus against human parainfluenza virus (PIV) types 1 and 2 using a recombinant PIV3 backbone. Tao T; Skiadopoulos MH; Davoodi F; Surman SR; Collins PL; Murphy BR Vaccine; 2001 Jun; 19(27):3620-31. PubMed ID: 11395195 [TBL] [Abstract][Full Text] [Related]
19. A live attenuated chimeric recombinant parainfluenza virus (PIV) encoding the internal proteins of PIV type 3 and the surface glycoproteins of PIV type 1 induces complete resistance to PIV1 challenge and partial resistance to PIV3 challenge. Tao T; Skiadopoulos MH; Durbin AP; Davoodi F; Collins PL; Murphy BR Vaccine; 1999 Mar; 17(9-10):1100-8. PubMed ID: 10195620 [TBL] [Abstract][Full Text] [Related]
20. Recombinant Ag85B vaccine by taking advantage of characteristics of human parainfluenza type 2 virus vector showed Mycobacteria-specific immune responses by intranasal immunization. Watanabe K; Matsubara A; Kawano M; Mizuno S; Okamura T; Tsujimura Y; Inada H; Nosaka T; Matsuo K; Yasutomi Y Vaccine; 2014 Mar; 32(15):1727-35. PubMed ID: 24486310 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]